Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action

GC Shih, DJ Calkins - Expert Review of Ophthalmology, 2012 - Taylor & Francis
GC Shih, DJ Calkins
Expert Review of Ophthalmology, 2012Taylor & Francis
Primary open-angle glaucoma, a long-term degenerative ocular neuropathy, remains a
significant cause of vision impairment worldwide. While many risk factors have been
correlated with increased risk for primary open-angle glaucoma, intraocular pressure (IOP)
remains the only modifiable risk factor and primary therapeutic target. Pharmacologic
therapies are administered topically; these include α2-agonists, β-antagonists,
prostaglandin analogs and carbonic anhydrase inhibitors. Some of these topical …
Primary open-angle glaucoma, a long-term degenerative ocular neuropathy, remains a significant cause of vision impairment worldwide. While many risk factors have been correlated with increased risk for primary open-angle glaucoma, intraocular pressure (IOP) remains the only modifiable risk factor and primary therapeutic target. Pharmacologic therapies are administered topically; these include α2-agonists, β-antagonists, prostaglandin analogs and carbonic anhydrase inhibitors. Some of these topical medications exhibit secondary neuroprotective effects independent of their effect on IOP. This review covers the possible mechanisms of neuroprotection stimulated by drugs currently marketed for the lowering of IOP, based on known literature. While the neuroprotective properties of many glaucoma pharmaceuticals are promising from an experimental standpoint, key challenges for the development of new clinical practices include unknown systemic side effects, limited methods of drug delivery to the retina and optic nerve, and development of extended-release formulations.
Taylor & Francis Online